Neutralizing antibodies respond to a bivalent dengue DNA vaccine or/and a recombinant bivalent antigen

ZHI-SHAN ZHANG¹, YU-WEI WENG², HAI-LONG HUANG², JIAN-MING ZHANG² and YAN-SHENG YAN²

¹Clinical Laboratory, Affiliated Quanzhou First Hospital of Fujian Medical University; ²Fujian Center for Disease Control and Prevention, Fuzhou, Fujian 350001, P.R. China

Received November 22, 2013; Accepted June 10, 2014

DOI: 10.3892/mmr.2014.2850

Abstract. There is currently no effective vaccine to prevent dengue infection, despite the existence of multiple studies on potential methods of immunization. The aim of the present study was to explore the effect of DNA and/or recombinant protein on levels of neutralizing antibodies. For this purpose, envelope domain IIIIs of dengue serotypes 1 and 2 (DEN-1/2) were spliced by a linker (Gly-Gly-Ser-Gly-Ser), and cloned into the prokaryotic expression plasmid pET30a (+) and eukaryotic vector pcDNA3.1 (+). The chimeric bivalent protein was expressed in Escherichia coli, and one-step purification by high-performance liquid chromatography was conducted. Protein expression levels of the DNA plasmid were tested in BHK-21 cells by indirect immunofluorescent assay. In order to explore a more effective immunization strategy and to develop neutralizing antibodies against the two serotypes, mice were inoculated with recombinant bivalent protein, the DNA vaccine, or the two given simultaneously. Presence of the specific antibodies was tested by ELISA and the presence of the neutralizing antibodies was determined by plaque reduction neutralization test. Results of the analysis indicated that the use of a combination of DNA and protein induced significantly higher titers of neutralizing antibodies against either DEN-1 or DEN-2 (1:64.0 and 1:76.1, respectively) compared with the DNA (1:24.7 and 1:26.9, DEN-1 and DEN-2, respectively) or the recombinant protein (1:34.9 and 1:45.3 in DEN-1 and DEN-2, respectively). The present study demonstrated that the combination of recombinant protein and DNA as an immunization strategy may be an effective method for the development of a vaccine to prevent dengue virus infection.

Introduction

Dengue fever (DF), a mosquito-borne viral disease caused by the dengue virus, is one of the most common infectious diseases in tropical and subtropical regions. Patients infected with dengue virus exhibit various clinical symptoms with different levels of infection, from self-limited DF to life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) (1). Currently, there is no effective antiviral therapy for patients with DF, and the lack of effective mosquito control measures in dengue endemic areas maintains a high incidence of dengue infection. Developing dengue vaccines may provide a realistic approach for controlling dengue infections.

Dengue viruses are members of the family Flaviviridae and exist as four antigenically distinct serotypes (DEN-1–4) (2). This has been a major hindrance to vaccine development, as an individual who has experienced a single dengue virus infection develops neutralizing antibodies to that specific serotype, but remains susceptible to the other three serotypes of dengue virus. The cross-reactive, non-neutralizing antibody from the first dengue infection may bind to other serotypes of dengue virus, enhancing the uptake of virions into monocytic cell lines through interaction with cell surface immunoglobulin (Ig) receptors. This is a phenomenon known as antibody-dependent enhancement of infection (ADE) (3). The mechanism of ADE is considered as an important contributing factor to DHF and DSS (4). Therefore, an effective dengue vaccine must induce long-lasting and tetravalent type-specific neutralizing antibodies against all four serotypes. At present, there is no effective vaccine available, despite much research into methods of immunization for dengue infection. Early efforts to develop a dengue vaccine used the live attenuated virus (5,6) and inactivated whole virus vaccinations (7). Other approaches have focused on recombinant strategies, including the use of chimeric viruses encoding an antigen gene (8–10), antigen-encoding plasmids (11–13) and recombinant subunit antigens produced by heterologous expression systems (14–18).

The envelope (E) protein is the major structural protein of the dengue virus, and the majority of the recombinant vaccine strategies of previous studies have focused on it, due to its biological function of host cell surface receptor binding (19). Previous studies have demonstrated that the E protein is able to induce neutralizing antibodies and protective immunity (14,20). Further crystallographic studies have indicated

Correspondence to: Dr Yan-Sheng Yan, Fujian Center for Disease Control and Prevention, 76 Jintai Road, Fuzhou, Fujian 350001, P.R. China
E-mail: yanysh_fj@163.com

Key words: dengue vaccine, dengue virus, envelope protein, domain III, immunogenicity
that the E proteins from dengue viruses and other flaviviruses contain three structural domains (I, II and III) (21,22). Domain III (DIII) is an independent IgG-like folding domain (23) that contains multiple type- and subtype-specific neutralizing epitopes and host cell receptor recognition sites (19,24-27). Furthermore, it has been reported that either recombinant fusion proteins (15,17) containing an envelope or plasmid-encoding DIII gene (11,12) were able to induce neutralizing antibodies in mice. It has also been demonstrated that the fusion DIII protein does not elicit cross-reactive antibodies to heterologous dengue virus serotypes (15).

In the present study, domain III of the E protein (defined as EDIII) of the dengue type 1 and 2 viruses were spliced with a flexible peptide linker (Gly-Gly-Ser-Gly-Ser). The fusion gene was then subcloned into either a prokaryotic expression plasmid pET30a (+) or a eukaryotic expression vector pcDNA3.1 (+), then expressed in Escherichia coli and mammalian BHK-21 cells. The three immunization strategies were examined using the bivalent DNA vaccine, the recombinant bivalent antigen, or a combination of the two to determine whether the level of neutralizing antibodies is increased following immunization with a combination of two vaccines compared with levels of antibodies following a single vaccination.

Materials and methods

Materials. Escherichia coli host strains DH5α and BL21 (DE3) were purchased from Takara Biotechnology, Dalian, China. The expression plasmid pET30a (+) was obtained from Novagen (Darmstadt, Germany) and pcDNA3.1 (+) from Invitrogen Life Technologies (Carlsbad, CA, USA). DEN-2 virus-specific monoclonal antibody (mAb; 3H5) (catalog no. MA88702) was from Chemicon (Temecula, CA, USA). The secondary antibody-enzyme conjugates (anti-mouse IgG-alkaline phosphatase, anti-mouse IgG-fluorescein isothiocyanate conjugate) were obtained from SouthernBiol (Hilden, Germany) and pcDNA3.1 to generate pcDNA-D1DIII.  To create the D1/D2EDIII chimeric bivalent gene, fragment D2EDIII was digested with BamHI and XhoI and inserted into the BamHI and XhoI sites of pcDNA3a-D1.  The resulting pET30a-D1/2EDIII recombinant plasmid was identified by restriction analysis and sequencing.

To construct the recombinant eukaryotic expression vector, pET30a-D1/2EDIII was digested with KpnI and XhoI to release the chimeric bivalent gene, D1/2EDIII. The fragment D1/2EDIII was then ligated into the corresponding KpnI and BamHI restriction sites of the expression vector pET30a (+), generating a recombinant plasmid that was labeled as pET30a-D1EDIII. To create the D1/D2EDIII cDNA sequence, fragment D2EDIII was digested with BamHI and XhoI and inserted into the BamHI and XhoI sites of pET30a-D1EDIII. The resulting pET30a-D1/2EDIII recombinant plasmid was identified by restriction analysis and sequencing.

Expression and purification of recombinant pro-D1/D2EDIII protein in E. coli. E. coli BL21 (DE3) were transformed with plasmid pET30a-D1/2EDIII and grown in lysogeny broth (LB) medium (Sigma-Aldrich, St Louis, MO, USA) containing 30 μg/ml kanamycin at 37°C until an optical density (OD) of 0.6 was reached. Then, 0.6 mM isopropylthiogalactoside (IPTG) was added. After 4 h, 1 ml of cells was harvested, lysed and analyzed by SDS-PAGE. The bacteria transformed with expression vector pET30a (+) were included as negative controls. To obtain large yields of recombinant protein, bacteria transfected with pET30a-D1/2EDIII were used to inoculate into 1 liter LB growth medium containing 30 μg/ml kanamycin (Sigma-Aldrich). When the stationary growth phase was reached, 0.6 mM IPTG was added to induce expression for 4 h. The cell pellet was obtained by centrifugation (4,000 x g for 10 min), resuspended in lysis buffer to 1 liter LB growth medium containing 30 μg/ml kanamycin (Sigma-Aldrich). Following centrifugation at 12,000 x g for 10 min, aliquots of the supernatant and the pellet were analyzed by SDS-PAGE to determine whether the recombinant protein was soluble.

The pellet containing the inclusion bodies was resuspended in solubilization buffer (20 mM Tris-HCl (pH 8.0), 5 mM EDTA, 100 mM NaCl and 8 M urea), diazoyzed overnight in dialysis buffer I (10 mM phosphate buffer (pH 6.0) and 4 M urea) and filtered through 0.22-μm-pore filter units (EMD Millipore, Billerica, MA, USA). The supernatant was applied to HPLC on a cation exchange column (TSKgel DEAE-5PW, Tosoh
Table I. Primers used in the present study.

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (5′-3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D1F</td>
<td>5′-GTGGTACCATGGACAAAACTGACCTTTAAAGGG-3′</td>
</tr>
<tr>
<td>D1R</td>
<td>5′-GTGGATCCAGAACCGCCAGATCCAGAGGACCCCCTACGCGGTGTCTTCTAG-3′</td>
</tr>
<tr>
<td>D2F</td>
<td>5′-GTGGATCCGCTGCTTGGATGACACTGACCTTTAAAGGG-3′</td>
</tr>
<tr>
<td>D2R</td>
<td>5′-GATCTCGAGTCACCAGGCTGTGTCACCTAAAAT-3′</td>
</tr>
</tbody>
</table>

Primers D1F and D1R were used to produce the D1EDIII gene. D1F contained 2/3 sequences of 5′-terminal linker (underlined). Primers D2F and D2R were used to generate the D2EDIII fragment. D2F contained 1/3 sequences of 3′-terminal linker. Primer D2R contained a stop codon (italics) at the C-terminal. Restriction sites (KpnI in D1F; BamHI in D1R and D2F; XhoI in D2R and D2His) are presented in bold.

Bioscience) pre-equilibrated with buffer I. The column was washed with buffer I for 30 min, then with a linear gradient from buffer I to buffer II (1 M NaCl in buffer I) for 60 min and finally washed with buffer II for 30 min. The elution fractions were collected and analyzed by SDS-PAGE. The elution containing the recombinant protein (designated as pro-D1/D2EDIII) was dialyzed against phosphate-buffered saline (PBS) to remove urea, and then the total protein from the E. coli transformants was analyzed by 12% SDS-PAGE, followed by Coomassie blue staining (Sigma-Aldrich).

Western blot analysis. Purified pro-D1/D2EDIII protein was purified by 12% SDS-PAGE and transfected electrophoretically to a nitrocellulose membrane. The membrane was blocked overnight with blocking buffer (5% non-fat dried milk in PBS; Sigma-Aldrich) and then incubated with primary antibody (either a serum from mouse polyclonal anti-DEN-1 EDIII or anti-DEN-2 EDIII antibody at 1:500 dilution in blocking buffer) at room temperature for 1 h. The membrane was washed with PBST (1X PBS containing 0.1% Tween 20) three times and reacted with alkaline phosphatase-conjugated goat anti-mouse IgG at 1:5,000 in blocking buffer for 1 h at 37°C. Following washing, the protein bands were detected with 5-bromo-4-chloro-3 indolyl phosphate (BCIP) and nitroblue tetrazolium chloride (NBT) (Sigma-Aldrich).

Cell transfection and immunofluorescence assay (IFA). BHK-21 cells were transfected with plasmid pcDNA-D1/2EDIII using Lipofectamine 2000 reagent (Life Technologies, Carlsbad, CA, USA). Cells were cultured in RPMI-1640 medium supplemented with 10% FBS without antibiotic at 37°C and 5% CO2. One day prior to transfection, cells were trypsinized and plated at a density of 1x10⁵ cells/well on six-well plates, so that they were 40-50% confluent on the day of transfection. A total of 2 µg pcDNA-D1/2 EDIII or pcDNA3.1 (+) (as negative control) was used and transfection was performed according to the manufacturer’s instructions. Cells were analyzed 48 h post-transfection by indirect IFA using either a mouse polyclonal antibody prepared against purified bacterial expressed pro-D1/D2EDIII protein or mAb 3H5. Briefly, cells were washed once with PBS, air dried, fixed with ice-cold acetone and incubated for 45 min at 37°C with either polyclonal anti-pro-D1/D2EDIII antibody (at 1:40 dilution in 0.01 M PBS) or 3H5 mAb (at 1:200 dilution in 0.01 M PBS). Cells were washed with PBS three times, incubated for 30 min with fluorescein-conjugated goat anti-mouse IgG (at 1:50 dilution in 0.01 M PBS), and detected under a fluorescent microscope.

Mouse immunization and antibody detection. Groups of BALB/c mice (4-6 weeks old; Huafukang Biotechnology Ltd., Beijing, China) were immunized intraperitoneally with 50 µg recombinant pro-D1/D2EDIII protein emulsified with Freund’s complete adjuvant (PRO group) and/or 100 µg pcDNA-D1/2EDIII (DNA group or PRO/ DNA group) on day 0, 14 and 28. The mice were maintained under a light/dark cycle, at 25°C. Negative control mice received PBS at similar time-points. Blood was obtained from the mice 10 days after the final injection and sera were collected and stored at -70°C until use. The mice were sacrificed by cervical dislocation 28 days after the final injection. Animal experiments were reviewed and approved by the Fujian Medical Research Center of Animal Care and adhered to the guidelines of the Government of China.

The antibody titers of mouse sera were evaluated by an indirect ELISA approach. Each of the monovalent DEN-1 and DEN-2 EDIII proteins (pro-D1EDIII, pro-D2EDIII) were used as a capture antigen to assess serotype specificity of antisera. Following coating for 2 h at 37°C with pro-D1EDIII or pro-D2EDIII (100 ng in 100 µl/well), 96-well microplates were blocked with 1% bovine serum albumin in PBS-Tween 20 for 2 h at 37°C, washed three times with PBS-Tween 20 and incubated with serial two-fold dilutions of mouse sera for 30 min at 37°C. The wells were then washed a further three times and incubated with peroxidase-conjugated goat anti-mouse IgG (1:5,000 dilution in blocking buffer) at 37°C for 30 min. Following washing, three times, 3,3′-5,5′-tetramethyl benzidine substrate (100 µl/well) was added and the samples were incubated at 37°C for 15 min. The reaction was stopped by adding 50 µl of 1 M H2SO4 and the absorbance of each well was read at 450 nm using a microplate reader (GelDox XR; Bio-Rad Laboratories, Hercules, CA, USA).

Neutralizing antibody titers were determined by plaque reduction neutralization test (PRNT) using either DEN-1 or DEN-2 virus with BHK-21 cells, as previously described (29). The neutralization titer was defined as the maximal dilution yielding a 50% reduction in the number of plaque-forming units, expressed as the PRNTt50 titer.

Statistical analysis. Logarithmic transformations of the reciprocal PRNTt50 titers of the mice in each immunization group
were made, and the mean log titers were compared by analysis of variance. The mean log titers were converted to geometric mean (GM) titers for presentation. P-values were calculated using SAS version 8.2 statistical software (SAS Inc., Cary, NC, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Creation of recombinant expression vectors. The construction of the recombinant pET30a-D1/2EDIII is illustrated in Fig. 1A. This construct was predicted to encode a 335-aa recombinant protein with a molecular weight of 37 kDa, and verified to be correct by restriction and sequencing (data not shown).

The D1/2EDIII chimeric bivalent gene was obtained from pET30a-D1/2EDIII by restriction digestion with Kpnl/Xhol and cloned into the eukaryotic expression vector pcDNA3.1 (+) under the control of the cytomegalovirus promoter. A His tag was used to construct pcDNA-D1/2EDIII (Fig. 1B). The recombinant plasmid was correctly expressed in transfected BHK-21 cells, as demonstrated by IFA results (Fig. 2). The pcDNA-D1/2EDIII-transfected cells manifested a strong fluorescent signal when detected with either polyclonal anti-pro-D1/D2EDIII antibody or 3H5 mAb (Fig. 2A and C), compared with cells transfected with pcDNA3.1 (+) (Fig. 2Band D).

Expression and purification of recombinant pro-D1/D2EDIII bivalent protein in E. coli. The recombinant plasmid pET30a-D1/2EDIII was transformed into E. coli BL21 (DE3), and expression was induced by IPTG for ~4 h. Total protein from E. coli transformants was analyzed by 12% SDS-PAGE followed by Coomassie blue staining. As displayed in Fig. 3A, a dominant band corresponding to the predicted size was detected.
in the pellet from bacteria carrying pET30a-D1/D2EDIII (lane 2) but not from cells transformed with pET30a alone (lane 3). To examine the relative distribution of expressed recombinant protein in the soluble or insoluble fraction, 1 liter culture of bacteria transformed with pET30a-D1/D2EDIII was prepared. The cell pellets were suspended in lysis buffer and sonicated. Following centrifugation, the supernatant and the pellet fractions were analyzed by SDS-PAGE. No dominant band was detected in the supernatant of the cell lysates (Fig. 3A, lane 4), but the majority of the expressed recombinant protein was associated with the pellet fraction (Fig. 3A, lane 5). Hence, the recombinant protein was present in the form of inclusion bodies.

The insoluble inclusion bodies were lysed in 8 M urea, dialyzed in buffer I and applied to an HPLC cation exchange column. The fractions, eluted with varying concentrations of NaCl for different time periods, were collected and analyzed by SDS-PAGE (data not shown), which indicated that the 37 kDa pro-D1/D2EDIII protein was eluted at 44-46 min. The 44-46 min fractions were pooled and dialyzed to eliminate urea, and thus, purified D1/D2EDIII protein was obtained. As demonstrated in Fig. 3B, lane 2, a single band of 37 kDa was
obtained following the purification steps, the final concentration of the purified protein was 1.05 mg/ml. Thus, ~20 mg of purified protein was obtained from a liter culture of induced cells.

In order to demonstrate that the recombinant bivalent protein preserves the antigenicity of DEN-1 and DEN-2 EDIII, purified pro-D1/D2EDIII was detected by western blot assay using sera from mouse polyclonal anti-DEN-1 EDIII or anti-DEN-2 EDIII antibodies. The results are presented in Fig. 3C. The anti-DEN-1 EDIII or anti-DEN-2 EDIII antibody was able to recognize the chimeric pro-D1/2EDIII protein (lanes 2 and 3).

**Serum antibody response in mice.** All of the mice inoculated with recombinant protein or and DNA demonstrated an IgG antibody response against either pro-D1EDIII (Fig. 4A) or pro-D2EDIII (Fig. 4B). The OD value of the PRO/DNA group was the highest and the D group was the lowest, while the PRO group exhibited an intermediate response. PBS-immunized sera did not display significant ELISA reactivity against pro-D1EDIII or pro-D2EDIII.

To evaluate the ability of antibodies to neutralize the DEN-1 and DEN-2 viruses, PRNT was performed. The results are summarized in Table II. The GM PRNT_{50} titers of the PRO/DNA group against either DEN-1 or DEN-2 were significantly higher than those of the PRO group (P<0.05), which were significantly higher than those of the DNA group (P<0.05).

**Discussion**

The development of a dengue vaccine continues to be a challenge, as the vaccine must protect against four serotypes of dengue virus without eliciting the ADE reaction in order to be effective. Previous approaches have focused on live attenuated dengue virus, and development of a ‘tetravalent’ formulation by mixture of four monovalent dengue serotypes (5,30-34). However, simple physical mixture may lead to a predominant immune response towards a single serotype of dengue virus, which has been attributed to viral interference (8,33,35,36). Recently, increasing attention is being focused on the recombinant strategies, mainly based on subunit proteins or DNA plasmids.

The EDIII of the DEN-2 virus has been successfully expressed in *E. coli* with or without fusion protein (15,17,37), and these investigations demonstrated that the recombinant DEN-2 EDIII protein has the biological function of blocking the virus from binding to host cells (37) and the ability to

---

**Table II. Virus-neutralizing antibody titers in sera of immunized mice.**

<table>
<thead>
<tr>
<th>Immuneogen</th>
<th>DEN-1</th>
<th>DEN-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRO (n=8)</td>
<td>34.9</td>
<td>45.3</td>
</tr>
<tr>
<td>DNA (n=8)</td>
<td>24.7</td>
<td>26.9</td>
</tr>
<tr>
<td>PRO/DNA (n=8)</td>
<td>64.0</td>
<td>76.1</td>
</tr>
<tr>
<td>PBS (n=8)</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

PRO, recombinant protein; DNA, DNA vaccine; PRO/DNA, combination of PRO and DNA; PBS, mock immunized with phosphate-buffered saline; GM, geometric mean; ND, no detectable neutralizing antibody titer; PRNT, plaque reduction neutralization test; DEN-1/2, dengue serotype 1/2. **
elicit a neutralizing antibody reaction (15,17). A tetravalent dengue vaccine, created by physically mixing four monovalent components into a single formulation based on domain III, has also been studied (12,16). However, a single tetravalent vaccine has a clear advantage over a mixture of four ‘monovalent’ components, as it provides a significant cost benefit and has the potential to eliminate non-uniform immune responses.

In the present study, a bivalent dengue subunit vaccine and DNA vaccine were constructed using a prokaryotic expression plasmid or eukaryotic expression vector containing a bivalent gene, obtained by splicing EDIIIs of dengue virus serotypes 1 and 2. A recombinant plasmid pET30a-D1/2EDIII was created by splicing the EDIII genes of DEN-1 and 2. A linker (Gly-Gly-Ser-Gly-Ser), was introduced to maintain structure integrity and biological function of the two serotype-specific EDIII proteins, taking advantage of glycine’s lack of a β carbon and serine’s propensity of hydrogen bonding (38). The recombinant bivalent antigen was successfully expressed in E. coli and purified by HPLC with a yield of ~20 mg/liter. To verify whether the purified pro-D1/D2EDIII protein still retained the antigenicity of the monovalent EDIIIs it was derived from, a western blot analysis was performed using mouse polyclonal anti-DEN-1 or DEN-2 EDIII antibodies. The results demonstrated that the recombinant bivalent protein was recognized by the anti-DEN-1 or DEN-2 EDIII antibodies. Furthermore, the result of the ELISA indicated that the antibodies from mice immunized with the recombinant protein may react with monovalent pro-D1EDIII and D2EDIII at high levels. It is possible that the recombinant bivalent protein preserved the antigenic integrity of its precursors.

Furthermore, it was determined whether these antibodies were able to neutralize the DEN-1 and DEN-2 viruses. The PRNT data indicated that the GM PRNT50 titers of antibody were 34.9 for DEN-1 and 45.3 for DEN-2. Neutralizing antibody titers are widely accepted as markers of protective immunity, with PRNT50 titers of 1:10 being considered indicative of protective immunity (39,40). The present study suggested that the recombinant bivalent protein was able to produce protective antibodies against the DEN-1 and DEN-2 viruses. These results are similar to those obtained by Khanam et al (41), who created a chimeric dengue antigen expressed in E. coli by splicing EDIIIs of virus serotypes 2 and 4 that was able to elicit neutralizing antibodies against dengue virus serotypes 2 and 4. The titers of neutralizing antibodies have been demonstrated to be lower than those induced by EDIII-MBP proteins (16). The contrast is theorized to be attributed to the differences of the experimental parameters of the PRNT assays and the host cells that were used. Furthermore, the uncertainty of the carrier activity and safety of MBP in humans causes an obstacle in the application of these fusion proteins in a vaccine.

Promising DNA vaccines have been developed against the dengue virus previously. Mota et al (12) developed a tetravalent DNA vaccine consisting of a mixture of four plasmids, each encoding EDIII genes specific to one DEN serotype. However, extrapolation from the study by Mota et al (12) was limited as only the level of DEN-2 neutralizing antibodies was examined and the other three serotypes were not evaluated. In the present study, a pcDNA-D1/2EDIII recombinant plasmid was generated, which, as a bivalent gene, encoded the EDIIIs of DEN-1 and 2. To develop an effective DNA vaccine, it is essential that the recombinant protein, encoded by the DNA plasmid, is expressed correctly (42). The result of IFA indicated that cells transfected with pcDNA-D1/2EDIII were able to react with anti-pro-D1/D2EDIII antibody (Fig. 2A) or the 3H5 mAb (Fig. 2C), which is specific to DEN-2 EDIII (29,30). The results of the present study suggested that the recombinant plasmid pcDNA-D1/2EDIII was capable of being expressed adequately in mammalian cells. The GM PRNT50 titers induced by DNA were 24.7 for DEN-1 and 26.9 for DEN-2, which is in contrast with the neutralizing antibody level of ~1:10 that was reported by Mota et al (12).

It has previously been reported that the use of a combination of DNA vaccine and recombinant protein with a prime-boost strategy can induce higher antibody titers than the individual vaccines alone (11,43,44). A study by Simmons et al (11) indicated that the combination of a DEN-2 DNA vaccine coding for premembrane and E proteins and a recombinant fusion protein containing the domain III of the DEN-2 E protein fused to the maltose-binding protein (MBP) induced higher neutralizing titers than the DNA or protein alone. In the current study, various immunization strategies were tested to observe whether it is possible to increase the level of neutralizing antibodies against DEN-1 and DEN-2 induced by a combination of DNA and protein, compared with when the vaccines were used alone. The results indicated that when mice were immunized with a combination of DNA and protein, significantly higher titers of neutralizing antibodies against either DEN-1 or DEN-2 (64.0 or 76.1, respectively) were observed, compared with titers following vaccination with the DNA or the recombinant protein alone. Similar antibody responses were observed using ELISA, and an association between total antibody levels measured by ELISA and neutralizing antibody titers was indicated. This result is in contrast with the study by Simmons et al (11), which noted a lack of correlation between total antibody levels and PRNT50 titers. This contrast may be explained by the fact that Simmon et al (11) had a larger number of total epitopes available in the DNA vaccine coding for the premembrane and E proteins, whereas the present study used only domain IIIIs for the construction of a DNA vaccine.

In conclusion, a recombinant prokaryotic/eukaryotic expression plasmid containing fusion EDIIIs of DEN-1 and DEN-2 was successfully constructed in the present study, using a flexible peptide linker. The recombinant protein and DNA vaccines were able to induce neutralizing antibodies against DEN serotypes 1 and 2. The current strategies used to construct fusion bivalent genes, expression and one-step purification are valuable in developing an inexpensive scale-up tetravalent dengue subunit vaccine or DNA vaccine. However, the combination of bivalent DNA and the recombinant protein resulted in higher levels of neutralizing antibodies, and may have the potential to induce improved cell-mediated immune responses in addition to humoral immune responses, compared with DNA or protein subunit vaccines alone. Further studies are required to assess the ability to release cytokines and the duration of neutralizing antibodies in response to the three immunization strategies (DNA vaccine, recombinant subunit vaccine, or a combination of the two).
References

24. Crill WD and Roehrig RT: Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75: 7769-7773, 2001.